Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Follows Novartis; Offers To Up Stake In Indian Arm To 75 Percent

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After Novartis and Mylan, it's now Pfizer's turn to increase its equity holding in its Indian operations. In an announcement to the Bombay Stock Exchange, Pfizer said it has decided to acquire an additional stake of 33.77 percent in Pfizer India through an open offer from public shareholders at a price of 675 rupees per share ($13.23)

You may also be interested in...



GSK Pumps In $1 Billion To Raise Equity In Indian Pharma Subsidiary

GSK said it will infuse $1 billion to purchase shares and raise its stake in its Indian arm to 75%, the highest limit allowed in India. Brushing aside the growth setback in the last few months, the British firm reaffirmed a long view of the Indian health care market.

Listing Of MNC Divisions In India Has Been Rough Ride With Stray Sparks Of Hope

Large pharmaceutical companies realize the importance of emerging markets, including India, and are now calling for easing of restrictions and a level playing field.

Listing Of MNC Divisions In India Has Been Rough Ride With Stray Sparks Of Hope

Large pharmaceutical companies realize the importance of emerging markets, including India, and are now calling for easing of restrictions and a level playing field.

Related Content

UsernamePublicRestriction

Register

SC071317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel